Presently, CSF Aβ42 and the Aβ42/40 ratio, CSF total tau, and phosphorylated tau are widely recognized as extensive tests for clinical AD diagnosis (Kerwin et al., 2022). The gene discussed is MAPT; the disease is Alzheimer disease.